Hospital Universitario Austral - Pilar
Hospital Universitario Austral - Pilar
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Silvio Carricondo
Gustavo Daniel Kusminsky
Sofia Blotta
Pablo Maid
Luis Ignacio Daverede
Andrés Nicolás Atamañuk
Hernán Amartino
Marcelo Silva
Cristina Alonso
Diego Arufe
Gabriela Marinsalta
David Veron
Open studies
Myeloproliferative syndromes
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) - Merck Sharp & Dohme LLCSee more
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) - Merck Sharp & Dohme LLCSee more
Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin - VOLGA - AstraZenecaSee more
Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis - ELFIDENCE - IpsenSee more
Kidney cancer
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma - STELLAR-304 - ExelixisSee more
Lupus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
Multiple myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) - MagnetisMM-32 - PfizerSee more
Skin cancer
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) - V940-007 - Merck Sharp & Dohme LLCSee more
